{"id":19522,"date":"2025-03-03T06:00:57","date_gmt":"2025-03-03T06:00:57","guid":{"rendered":"https:\/\/interhospi.com\/?p=19522"},"modified":"2025-02-25T03:56:07","modified_gmt":"2025-02-25T03:56:07","slug":"edx-medical-develops-comprehensive-multi-biomarker-test-for-prostate-cancer","status":"publish","type":"post","link":"https:\/\/interhospi.com\/edx-medical-develops-comprehensive-multi-biomarker-test-for-prostate-cancer\/","title":{"rendered":"EDX Medical develops comprehensive multi-biomarker test for prostate cancer"},"content":{"rendered":"
\n

<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

EDX Medical develops comprehensive multi-biomarker test for prostate cancer<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Cambridge-based scientists have developed a novel diagnostic approach for prostate cancer detection, utilising advanced biomarker analysis and AI interpretation. The test, developed by EDX Medical Group, aims to transform screening accuracy by simultaneously evaluating over 100 clinically validated biomarkers in both blood and urine samples.<\/strong><\/p>\n

<\/p>\n

\"EDX<\/h3>\n

Multi-omics approach enhances diagnostic precision<\/strong><\/h3>\n

The new diagnostic protocol combines proteomic, transcriptomic, genetic and epigenetic biomarker signatures to create a comprehensive profile of prostate cancer status. This multi-omics methodology enables the detection of various cancer subtypes with anticipated sensitivity and specificity between 96-99%, significantly outperforming current standard-of-care testing which can fall below 50% accuracy.<\/p>\n

All biomarkers incorporated into the test have been independently validated through clinical trials involving more than 31,000 positive prostate cancer samples and 100,000 control samples. The test\u2019s proprietary AI algorithm integrates these molecular signatures with phenotypic and symptom data to produce detailed diagnostic reports.<\/p>\n

Addressing clinical limitations of current testing protocols<\/strong><\/h3>\n

The EDX test aims to overcome significant limitations of traditional prostate-specific antigen (PSA) testing, which research indicates can be unreliable for definitive diagnosis. Approximately 70% of men with elevated PSA do not have cancer, while around 20% with normal or low PSA levels may have undetected cancer, often of aggressive subtypes.<\/p>\n

Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, explained: \u201cOur integrated approach highlights the potential of combining these molecular signatures, offering a powerful, non-invasive diagnostic tool that can certainly improve clinical outcomes and help personalise treatment for patients.\u201d<\/p>\n

Potential to reduce unnecessary interventions<\/strong><\/h3>\n

Implementation of the test could potentially reduce the need for invasive diagnostic procedures including digital rectal examinations and unnecessary MRI scans. The non-invasive nature of the blood and urine sampling makes it particularly suitable for population screening programmes.<\/p>\n

Dr Mike Hudson, chief executive of EDX Medical, stated: \u201cI\u2019m confident that the EDX testing strategy will define a new standard for the early detection and characterisation of emergent, prostate cancer, and provide unique insights to guide optimal treatment selection.\u201d<\/p>\n

Clinical validation and regulatory considerations<\/strong><\/h3>\n

The EDX scientific team plans to validate additional clinical data in the coming months before seeking regulatory approval from the Medicines & Healthcare Products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA). The company anticipates potential commercial availability in late 2025 or early 2026.<\/p>\n

The company has filed a patent application for both the test and its AI algorithm with the European Patent Office. This intellectual property protection covers the comprehensive analytical approach that distinguishes this test from competitors that typically rely on significantly fewer biomarkers.<\/p>\n

Epidemiological context<\/strong><\/h3>\n

Prostate cancer represents a substantial clinical burden across Europe, with approximately 55,000 new cases diagnosed annually in the UK and more than 330,000 across European Union countries. At any given time, more than one million men are undergoing treatment for the condition.<\/p>\n

The test\u2019s developers indicate it may provide particular benefits for high-risk demographic groups, including non-Caucasian men who demonstrate higher rates of advanced and aggressive disease presentations.<\/p>\n